ACT001 improves OVX-induced osteoporosis by suppressing the NF-κB/NLRP3 signaling pathway

Abstract Osteoporosis (OP) is a common systemic metabolic bone disease characterized by the decrease in bone mass and hyperactivity of osteoclasts. ACT001 is approved as an orphan drug by FDA and has shown multiple protective effects against tissue injury. However, its role in prevention of osteocla...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yuan Li, Jin-Yu Yang, Ma-Li Lin, Tian-Zhu Liu, Wen-Na Lu, Ying Yang, Zhong-Cheng Liu, Jian-Heng Li, Guo-Qiang Zhang, Jian-Shuang Guo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-04-01
coleção:	Molecular Medicine
Assuntos:	ACT001 Osteoporosis Osteoclastogenesis NF-κB pathway NLRP3 inflammasome
Acesso em linha:	https://doi.org/10.1186/s10020-025-01189-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!